Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Research & Development (2016 - 2025)

Regenxbio (RGNX) has 12 years of Research & Development data on record, last reported at $59.6 million in Q4 2025.

  • For Q4 2025, Research & Development rose 18.32% year-over-year to $59.6 million; the TTM value through Dec 2025 reached $228.3 million, up 9.48%, while the annual FY2025 figure was $228.3 million, 9.48% up from the prior year.
  • Research & Development reached $59.6 million in Q4 2025 per RGNX's latest filing, up from $56.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $63.3 million in Q3 2022 and bottomed at $39.7 million in Q1 2021.
  • Average Research & Development over 5 years is $54.6 million, with a median of $55.7 million recorded in 2022.
  • Peak YoY movement for Research & Development: soared 40.04% in 2022, then dropped 18.4% in 2024.
  • A 5-year view of Research & Development shows it stood at $48.0 million in 2021, then surged by 30.28% to $62.5 million in 2022, then decreased by 10.92% to $55.7 million in 2023, then dropped by 9.52% to $50.4 million in 2024, then increased by 18.32% to $59.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $59.6 million in Q4 2025, $56.1 million in Q3 2025, and $59.5 million in Q2 2025.